title: Response to questions regarding the design and results of the IMPACT trial.
authors.forename: Atul
authors.initials: A
authors.lastname: Humar
authors.forename: P
authors.initials: P
authors.lastname: Peeters
authors.forename: D
authors.initials: D
authors.lastname: Abramowicz
authors.forename: A
authors.initials: A
authors.lastname: Humar
authors.forename: Y
authors.initials: Y
authors.lastname: Lebranchu
authors.forename: I
authors.initials: I
authors.lastname: Hauser
authors.forename: A
authors.initials: A
authors.lastname: Jardine
authors.forename: A P
authors.initials: AP
authors.lastname: Limaye
authors.forename: F
authors.initials: F
authors.lastname: Vincenti
authors.forename: J D
authors.initials: JD
authors.lastname: Punch
authors.forename: E
authors.initials: E
authors.lastname: Blumberg
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D004311:Double-Blind Method; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016030:Kidney Transplantation; D011897:Random Allocation; D012107:Research Design; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir